The NLRP3 inflammasome plays a central role in inflammation-mediated sensorineural hearing loss (SNHL). Genetic and acquired activation causes cochlear damage through cytokine release and pyroptosis. Targeted therapies, including IL-1 blockers and novel NLRP3 inhibitors, offer hope for effective treatment of various SNHL forms.